| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Gallagher Duncan serves as a Director at HCAT. Across recent SEC filings that breaks down to 2 buys and 2 sells. Those positions are worth an estimated $227K at current prices.
Historically, Gallagher Duncan's trades have earned a middling insider score of 63/100 across 4 rated trades. Over a 12-month horizon, 100.0% of those trades were profitable, with an average 12-month return of +33.4%.
The biggest single holding is HCAT (~$227K) as Director. Net of sales, the recent Form 4 record there shows accumulation of 6,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 30, 2024 | HCAT Health Catalyst, Inc. | Director | Sell | 4,500 | $6.93 | $31,184.10 | -6.0% | -35.4% | -66.0% | |
| Dec 23, 2024 | HCAT Health Catalyst, Inc. | Director | Sell | 4,500 | $6.98 | $31,415.40 | -5.7% | -35.7% | -66.1% | |
| Aug 19, 2022 | HCAT Health Catalyst, Inc. | Director | Buy | 15,000 | $11.66 | $174,946.74 | +30.5% | -17.1% | +0.8% |